GenSight
Enterprise Resource Planning (ERP) · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
780 5th Ave S, Naples, Florida, 34102, U...Phone Number
(239) 261-9936Website
www.gensight.comRevenue
$14.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About GenSight
GenSight is a global leader in providing enterprise software solutions for strategy execution and project portfolio management. Their comprehensive platform supports various functions including digital transformation, new product development, and resource management, catering to leading corporations across diverse industries such as pharmaceuticals, healthcare, and telecommunications. With over 25 years of experience, GenSight empowers organizations to optimize resource allocation and enhance innovation performance. Their clients, including Fortune 100 companies, benefit from best-practice solutions that improve project prioritization, selection, and overall strategic management.Explore more
GenSight Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GenSight your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if GenSight is spiking on competitors!
Product Launch: Get notified when GenSight launches new products
Congratulate Masked Content for being promoted to Masked Content at GenSight
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on GenSight recently announced quarterly report
Click to see if GenSight had a recent Job posting/layoffs
Check if GenSight has recently received funding, and reach out quickly before it becomes old news!
GenSight, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GenSight has new funding data
Recommended Actions
Reach out to Masked Content who joined GenSight as Masked Content
Find 2 more new buyers
Compare Similar Companies to GenSight
Compare insights from companies similar to GenSight, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GenSight is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
GenSight is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about GenSight.
GenSight Tech Stack
A closer look at the technologies used by GenSight
GenSight News & Media
GenSight Biologics publie ses résultats financiers 2020 et fait un point sur les principaux enjeux 2021
PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, publie aujourd’hui ses résultats financiers pour l’exercice 2020 et fait un point sur les principaux enjeux 2021. Les procédures d’audit sur les comptes consolidGenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'intégralité des bons de souscription d'actions par Kreos Capital
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (Paris:SIGHT) (la « Société » ou « GenSight »), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce aujourd'hui avoir reçu, dans le cadre de son emprunt obligataire conclu avec Kreos Capital VI (Expert Fund) LP (« Kreos »GenSight Biologics annonce la validation de la demande d’autorisation de mise sur le marché (AMM) de LUMEVOQ® par l’Agence Européenne des Médicaments
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce aujourd’hui que la demande d'autorisation de mise sur le marché (AMM) de LUMEVOQ® a passé avec succès les contrôles de validation auxquels sont soumis lesGenSight’s latest upgrade enables customers to access additional features, offering greater freedom and control.
GenSight, a leader in Innovation Process Management software, has announced the release of its latest version, delivering dynamic and interactive reporting capabilities to help businesses understand, prioritize and manage project execution and support market success. (PRWeb November 08, 2019) Read the full story at https://www.prweb.com/releases/gensights_latest_upgrade_enables_customers_to_access_additional_features_offering_greater_freedom_and_control/prweb16704492.htm
Read more news
Top Enterprise Resource Planning (ERP) Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GenSight
Sign Up For FreeTo access detailed company insights
GenSight is a global leader in providing enterprise software solutions for strategy execution and project portfolio management. Their comprehensive platform supports various functions including digital transformation, new product development, and resource management, catering to leading corporations across diverse industries such as pharmaceuticals... Read More
